The 130-page document linked below explains in detail why the American Cancer Society may be far more interested in accumulating cash than curing any disease. The ACS has close ties to the mammography industry, the cancer drug industry, and the pesticide industry. It is riddled with conflict of interest.

And in fact, according to the report, the ACS has a reckless, if not criminal record on cancer prevention. Over and over again, they have promoted drugs and screening while ignoring environmental causes.

The report states, in part:

“The ACS … [has] long continued to devote virtually exclusive priority to research on diagnosis and treatment of cancer, with indifference to prevention, other than faulty personal lifestyle, commonly known as ‘blame the victim,’ … Not surprisingly, the incidence of cancer over past decades has escalated”.

We Lost the War on Cancer – Review of Alternative Cancer Therapies

eBook
Retail : $9⁹⁹
Now : $5⁹⁹

We have lost the war on cancer. At the beginning of the last century, one person in twenty would get cancer. In the 1940s it was one out of every sixteen people. In the 1970s it was one person out of ten. Today one person out of three gets cancer in the course of their life.

The cancer industry is probably the most prosperous business in the United States. In 2014, there will be an estimated 1,665,540 new cancer cases diagnosed and 585,720 cancer deaths in the US. $6 billion of tax-payer funds are cycled through various federal agencies for cancer research, such as the National Cancer Institute (NCI). The NCI states that the medical costs of cancer care are $125 billion, with a projected 39 percent increase to $173 billion by 2020.

The simple fact is that the cancer industry employs too many people and produces too much income to allow a cure to be found. All of the current research on cancer drugs is based on the premise that the cancer market will grow, not shrink.

John Thomas explains to us why the current cancer industry prospers while treating cancer, but cannot afford to cure it in Part I. In Part II, he surveys the various alternative cancer therapies that have been proven effective, but that are not approved by the FDA.